BC Innovations | Apr 10, 2019
Distillery Therapeutics

Antibody-drug conjugate targeting ALK could treat neuroblastoma

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Cell and mouse studies identified an ALK-targeting antibody-drug conjugate (ADC) that could help treat neuroblastoma. The ADC consists of an anti-ALK mAb linked to the generic chemotherapy drug thienoindole....
BioCentury | Aug 17, 2018
Finance

Location, location, biotech

Chinese real estate investor Xuechao Wang placed a bet on a domestic cancer start up 16 years ago, which helped pave the way for the country’s first homegrown targeted cancer therapy. Now, market growth in...
BC Innovations | Oct 24, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Patient sample and mouse studies suggest inhibiting the ALK - STING axis could help treat sepsis. In patient peripheral blood mononuclear cells (PBMCs), levels of ALK and STING were higher than in PBMCs from...
BC Week In Review | Jul 28, 2017
Clinical News

NCI launching Pediatric MATCH trial

NCI and the Children’s Oncology Group (COG) began the Phase II NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) to determine whether cancer therapies can be targeted effectively to a predefined set of genetic...
BC Extra | Jul 24, 2017
Clinical News

NCI launching Pediatric MATCH trial

NCI and the Children’s Oncology Group (COG) began the Phase II NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) to determine whether cancer therapies can be targeted effectively to a predefined set of genetic...
BC Week In Review | Jul 11, 2016
Clinical News

X-396: Phase III started

Xcovery began the open-label, U.S. Phase III eXalt3 trial to compare 225 mg oral X-396 once daily vs. oral Xalkori crizotinib twice daily in 28-day cycles in about 400 patients who have received <=1 prior...
BC Week In Review | Nov 3, 2014
Clinical News

X-396: Phase I/II data

Data from 17 evaluable patients with ALK-positive NSCLC in an open-label, U.S. Phase I/II trial showed that X-396 led to 10 partial responses and 2 cases of stable disease. In the 5 patients with progressive...
BC Week In Review | Nov 3, 2014
Company News

Xcovery, Betta Pharmaceuticals deal

Xcovery granted Betta (formerly Zhejiang Beta Pharma Co. Ltd. ) Chinese rights to Phase I/II oncology candidate X-396 . Xcovery said it will continue developing the anaplastic lymphoma kinase (ALK) inhibitor to treat ALK-positive non-small cell lung...
BC Innovations | May 19, 2011
Cover Story

The DDR is in

The clinical success of Pfizer Inc. 's crizotinib anaplastic lymphoma kinase (ALK) inhibitor illustrates that attacking oncogenic drivers can substantially improve outcomes in small groups of non-small cell lung cancer patients. Now, an international team...
Items per page:
1 - 9 of 9